Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Resapp Announces FDA 510(K) Submission for Sleepcheckrx

10/10/2021 | 06:19pm EST

ResApp Health Limited announced that it has submitted a 510 premarket notification to the US Food and Drug Administration for SleepCheckRx, a prescription-only, software-as-a-medical- device smartphone application for at-home sleep apnoea screening. The targeted time period for review of a 510 application by the FDA is 90 days. SleepCheckRx is ResApp's easy to use smartphone application that uses clinically accurate algorithms to assess a patient's risk of obstructive sleep apnoea by analysing breathing and snoring sounds during sleep. It requires no accessories or hardware other than a smartphone to make an assessment. In a 308 patient, prospective clinical study, the SleepCheckRx algorithms were tested against an American Academy of Sleep Medicine Type II sleep study performed simultaneously in the patient's home. In the study, the algorithms identified patients with mild, moderate, and severe OSA with a sensitivity of 85%, 83% and 83%, respectively. The algorithms had a specificity of 73%, 80% and 90%, respectively. SleepCheckRx would be made available to patients via a prescription from their healthcare provider. Patients will be provided a specific code allowing them to download SleepCheckRx from the App Store, with their results uploaded to a healthcare provider portal. FDA clearance would unlock a substantial market opportunity for ResApp. It is estimated that 42 million American adults suffer from sleep disordered breathing iii and three in ten men and almost one in five women have sleep apnoeaiv . It is further estimated that 75% of SDB cases remain undiagnosedv.


ę S&P Capital IQ 2021
All news about RESAPP HEALTH LIMITED
11/29RESAPP HEALTH : receives world's first regulatory approvals for cough counter smartphone a..
PU
11/28ResApp Health Secures Australian, European Approvals for Cough Counter App; Shares Rise..
MT
11/28ResApp Receives Regulatory Approvals for Cough Counter
CI
11/23ResApp Health Completes Recruitment for COVID-19 Study in India
MT
11/22RESAPP HEALTH : completes COVID-19 study recruitment in India
PU
11/22ResApp Health Limited Completes COVID-19 Study Recruitment in India
CI
11/18RESAPP HEALTH : New publication highlights challenges of diagnosing acute respiratory dise..
PU
11/18Resapp Health Limited Announces Publication of Clinical Study Data Analysed from its Br..
CI
11/17Resapp Health Signs Deal with Johnson & Johnson Arm for Use of App in a Clinical Trial;..
MT
11/17RESAPP HEALTH : secures contract with global pharmaceutical company
PU
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,74 M -4,74 M
Net cash 2021 6,40 M 4,48 M 4,48 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 51,6 M 36,2 M 36,1 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 80,9%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED-29.41%36
SNAP INC.-6.55%77 125
PERFECT WORLD CO., LTD.-34.81%5 821
KAKAO GAMES CORP.106.96%5 802
GRUBHUB INC.-19.36%5 591
ANGI INC.-30.28%4 622